WO2002030897A3 - Compositions and methods for regulating the nervous system - Google Patents

Compositions and methods for regulating the nervous system Download PDF

Info

Publication number
WO2002030897A3
WO2002030897A3 PCT/FR2001/003154 FR0103154W WO0230897A3 WO 2002030897 A3 WO2002030897 A3 WO 2002030897A3 FR 0103154 W FR0103154 W FR 0103154W WO 0230897 A3 WO0230897 A3 WO 0230897A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
methods
regulating
compositions
invention concerns
Prior art date
Application number
PCT/FR2001/003154
Other languages
French (fr)
Other versions
WO2002030897A2 (en
Inventor
Gilles Fillion
Michel Bourin
Herve Galons
Original Assignee
Gilles Fillion
Michel Bourin
Herve Galons
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilles Fillion, Michel Bourin, Herve Galons filed Critical Gilles Fillion
Priority to AU2001295689A priority Critical patent/AU2001295689A1/en
Publication of WO2002030897A2 publication Critical patent/WO2002030897A2/en
Publication of WO2002030897A3 publication Critical patent/WO2002030897A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention concerns compositions and methods for regulating the nervous system, in particular central and peripheral nervous system disorders, for preventive or curative purposes. The invention concerns in particular compounds capable of modifying the serotoninergic transmission of the brain and the periphery, and their therapeutic uses. More particularly, the invention concerns compounds capable of binding the allosteric site of serotonin receptors, having particular beneficial pharmacological and therapeutic properties. The invention also concerns methods for preparing said compounds, pharmaceutical compositions containing them, and their therapeutic uses.
PCT/FR2001/003154 2000-10-11 2001-10-11 Compositions and methods for regulating the nervous system WO2002030897A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001295689A AU2001295689A1 (en) 2000-10-11 2001-10-11 Compositions and methods for regulating the nervous system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012983A FR2815031A1 (en) 2000-10-11 2000-10-11 Heterocyclic and carbocyclic compounds have serotoninergic transmission modifying properties for the treatment of central and peripheral nervous disorders
FR00/12983 2000-10-11

Publications (2)

Publication Number Publication Date
WO2002030897A2 WO2002030897A2 (en) 2002-04-18
WO2002030897A3 true WO2002030897A3 (en) 2002-10-24

Family

ID=8855209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003154 WO2002030897A2 (en) 2000-10-11 2001-10-11 Compositions and methods for regulating the nervous system

Country Status (3)

Country Link
AU (1) AU2001295689A1 (en)
FR (1) FR2815031A1 (en)
WO (1) WO2002030897A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040336A1 (en) 2002-06-26 2005-03-30 Glaxo Group Ltd PIPERIDINE COMPOUND, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE SUCH COMPOUND
US20090054510A1 (en) * 2006-03-22 2009-02-26 H. Lundbeck A/S Method for identifying compounds for the treatment of depression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953568A (en) * 1958-03-03 1960-09-20 Ciba Pharm Prod Inc Derivatives of piperazine
US2988551A (en) * 1954-07-30 1961-06-13 Union Chimique Belge Sa Piperazine derivatives
DE2621082A1 (en) * 1975-05-13 1976-11-25 Andre Buzas PIPERAZINE DERIVATIVE, THE PROCESS FOR ITS MANUFACTURING AND ITS USE AS A MEDICINAL PRODUCT
WO1992001679A1 (en) * 1990-07-26 1992-02-06 Novo Nordisk A/S 1,4-disubstituted piperazines
US5846980A (en) * 1994-03-25 1998-12-08 Cooperation Pharmaceutique Francaise N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852450A (en) * 1958-01-09 1960-10-26 Rhone Poulenc Sa New indole derivatives
US3217011A (en) * 1965-05-07 1965-11-09 Sterling Drug Inc 1-(indolyglyoxalyl)-piperidines
FR2603583B1 (en) * 1986-09-05 1988-12-09 Andre Buzas BENZHYDRYLOXYETHYL-PIPERIDINE DERIVATIVES, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2015949A1 (en) * 1989-05-22 1990-11-22 Yasuo Ito Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
TW230771B (en) * 1990-08-09 1994-09-21 Sankyo Co
JPH0517443A (en) * 1991-07-11 1993-01-26 Hokuriku Seiyaku Co Ltd Piperidine derivative
KR100389192B1 (en) * 1997-04-25 2003-06-27 다케다 야쿠힌 고교 가부시키가이샤 Condensed pyridazine derivatives, their production and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2988551A (en) * 1954-07-30 1961-06-13 Union Chimique Belge Sa Piperazine derivatives
US2953568A (en) * 1958-03-03 1960-09-20 Ciba Pharm Prod Inc Derivatives of piperazine
DE2621082A1 (en) * 1975-05-13 1976-11-25 Andre Buzas PIPERAZINE DERIVATIVE, THE PROCESS FOR ITS MANUFACTURING AND ITS USE AS A MEDICINAL PRODUCT
WO1992001679A1 (en) * 1990-07-26 1992-02-06 Novo Nordisk A/S 1,4-disubstituted piperazines
US5846980A (en) * 1994-03-25 1998-12-08 Cooperation Pharmaceutique Francaise N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants

Also Published As

Publication number Publication date
WO2002030897A2 (en) 2002-04-18
AU2001295689A1 (en) 2002-04-22
FR2815031A1 (en) 2002-04-12

Similar Documents

Publication Publication Date Title
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2005007111A3 (en) Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
WO2005019179A3 (en) Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
AU4331400A (en) Neurotrophic substituted pyrimidines
WO2000051546A3 (en) Bupropion metabolites and methods of their synthesis and use
WO2001066543A3 (en) 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
MXPA05013711A (en) 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators.
WO2004108133A3 (en) Modulators of vr1 receptor
WO2002036596A3 (en) CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
EP1471909A4 (en) Pharmaceutical composition and method for treating disorders of the central nervous system
EP1494673A4 (en) Compounds having unique cb1 receptor binding selectivity and methods for their production and use
HUP0401210A3 (en) Use of nk-1 receptor antagonists for the preparation of pharmaceutical compositions treating of brain, spinal or nerve injury
CN104059013B8 (en) 1-aryl-3-azabicyclo [3.1.0] hexane: its preparation method and for treating the purposes of neuropsychiatric disorders
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
PT1666462E (en) N-[1h-indol-5-yl]naphthalene-1-sulphonamide derivatives and related compounds as serotonin 5-ht6 receptor antagonists for the treatment of disorders of the central nervous system
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
HUP0501017A2 (en) Methods and compositions for treatment of central nervous system disorders
WO2001098279A3 (en) Bis-arylsulfones
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
WO2000064423A3 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP